Chugai Pharmaceuticalの空売り状況は、投資家がChugai Pharmaceuticalの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Chugai Pharmaceutical (OTC:CHGCY) 株価情報, 空売り情報

CHUGAI PHARMACEUTICA

Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and Actemra for treating rheumatoid arthritis and covid patients.

CHUGAI PHARM UNSP/ADR by Chugai Pharmaceutical Co., Ltd.

Chugai Pharmaceutical Co Ltd

Chugai Pharmaceutical Co. Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CHGCY#OTC">CHGCY</a>) believes its anti-muscle-wasting drug could be used alongside Eli Lilly And Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">oral obesity pill</a>, orforglipron.
Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) is a major shareholder of Chugai, a Japanese pharmaceutical company. The company&#8217;s optimism stems from growing evidence that modern weight-loss drugs can lead to significant muscle loss, an issue Chugai thinks it can help address.
Hitoshi Iikura, a senior executive at Chugai, <a target="_blank" href="https://www.ft.com/content/4fd1fd94-0b70-48fb-861b-3bad6286ebae" rel="noreferrer noopener">told</a> the Financial Times the company has &#8220;high expectations&#8221; for combining GYM329, initially developed for spinal muscular atrophy (SMA), with orforglipron or similar therapies.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45769020/mounjaro-maker-eli-lilly-taps-swedish-firm-camurus-to-target-long-acting-obesity-market-in-870-million-deal" rel="noreferrer noopener">Mounjaro Maker Eli Lilly Taps Swedish Firm Camurus To Target Long-Acting Obesity Market In $870-Million Deal</a>
Orforglipron, which Lilly licensed from Chugai, showed strong late-stage trial results, matching the safety and efficacy of popular injectables like Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Wegovy and Ozempic and Lilly&#8217;s Zepbound and Mounjaro.
The drug significantly <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44934811/eli-lilly-positioned-to-dominate-obesity-market-with-oral-option-analyst-initiates-with-confidence" rel="noreferrer noopener">reduced weight and blood sugar levels</a> and is expected to hit the market next year.
Chugai began developing orforglipron in 2003 as part of an effort to enhance diabetes treatments, aiming to make them longer-acting and tablet-based. Although obesity wasn&#8217;t an initial target, the company saw broader potential as research evolved. &#8220;We didn&#8217;t anticipate it but it&#8217;s ballooning,&#8221; Iikura said, referring to the unexpectedly large obesity market.
Studies suggest that 25% to 39% of weight loss from obesity drugs may be due to lean mass reduction, which includes muscle. Chugai argues that maintaining muscle mass is vital, especially for aging populations, and its GYM329 drug could be a key component in preventing this loss during weight-loss treatment.
Despite Chugai&#8217;s success, Roche had previously passed on orforglipron due to setbacks with an earlier weight-loss drug. At the time, much of the pharmaceutical industry was hesitant to enter the obesity space, except companies like Lilly and Novo Nordisk with strong metabolic disease portfolios.
However, with market interest and scientific breakthroughs accelerating, Roche reversed course in 2023 and <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40422774/roche-misses-out-on-weight-loss-blockbuster-drug-now-playing-catch-up-in-booming-market" rel="noreferrer noopener">reentered the field</a>.
Meanwhile, Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-06-07/lilly-s-obesity-drug-sales-rise-60-in-india-amid-rising-demand" rel="noreferrer noopener">reported</a> that Eli Lilly saw a 60% jump in sales of its weight-loss and diabetes drug Mounjaro in India in May compared to April, marking its second full month on the Indian market.
India has the third-largest obese population in the world.
According to market research firm Pharmarack Technologies, the U.S. drugmaker made 126 million rupees ($1.5 million) from Mounjaro injections last month.
Sales of the 5 mg dose more than doubled to 75 million rupees, while the 2.5 mg version brought in 51 million rupees.
According to the Indian Council of Medical Research (ICMR), there are 101 million people with diabetes in India. Of these, at least 40 million are on medication.
Vishal Manchanda, SVP of institutional research at Systematix Group,&nbsp;told&nbsp;Livemint that even if 0.5% of 40 million use Mounjaro, it would fetch Eli Lilly sales of <a target="_blank" href="https://www.benzinga.com/25/04/44824190/eli-lillys-mounjaro-launch-triggers-weight-loss-craze-in-india-novo-nordisk-seeks-to-move-up-wegovy-launch" rel="noreferrer noopener">$1.5 billion annually</a>.
Novo Nordisk&nbsp;is also trying to move up the launch of Wegovy in India to better compete with Lilly.
Price Action: LLY stock closed up 0.55% at $769.88 on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45814068/novo-nordisks-wegovy-tied-to-increased-risk-of-rare-vision-loss-disorder-european-regulators-say" target="_blank" rel="noreferrer noopener">Novo Nordisk&#8217;s Wegovy Tied To Increased Risk Of Rare Vision-Loss Disorder, European Regulators Say</a></li>
</ul>
Photo via Shutterstock

Biotech

News

Health Care

General

CHGCY

RHHBY

Eli Lilly's Obesity Drug Success Spurs Japanese Biotech's Anti-Muscle-Wasting Combo Therapy

On Friday, shares of Chugai Pharm Co (OTC: <a class="ticker" href="https://www.benzinga.com/stock/chgcy#OTC">CHGCY</a>) experienced volatile short activity. After the activity, the stock price went up +0.46% to $13.21.
The overall sentiment for CHGCY has been Bearish.
The signal from the volatility alert is trending Bearish. Therefore, the recommendation is to Increase Short Exposure.
The volatility alert was produced on the prior trading date, 12/9/2022 with a volatility change of +135.31%. The current volatility indicator stands at 10.873.
Overview: The securities lending volatility indicator is produced by Tidal Markets, in partnership with Benzinga Insights. Securities lending primarily serves the purpose of providing liquidity to short sellers. When unusual activity occurs in the securities lending markets, it acts as an upstream indicator to what is likely to occur downstream in the regular stock market.
Understanding the Volatility Alert: Overall sentiment is considered &quot;bear&quot; when broad market activity of the stock has been shown to indicate a negative directional basis, or is considered &quot;bull&quot; when indicating a positive directional basis. The securities lending volatility indicator provides a signal when it detects unusual short activity. Unusual short activity is based off a computer generated algorithmic formula utilizing securities lending trade details such as the volume of shares being shorted, the rate being paid to short the shares, and the type of collateral being posted - amongst other variables. The current volatility is the respective trading day&#39;s calculated securities lending volatility value. The volatility percentage change is the percentage difference in volatility between the two most recent days. The recommendation is a suggestive strategy, inferred from the strength of the Signal Trending, Current Volatility, and Volatility % Change. Recommendations may include, &quot;Strong Buy&quot;, &quot;Strong Sell&quot;, &quot;Increase Short Exposure&quot;, &quot;Decrease Short Exposure&quot;, or &quot;Market Neutral&quot;.
ANY INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE OR IMPLY INVESTMENT ADVICE

Short Ideas

Trading Ideas

Short Volatility Alert: Chugai Pharm Co

Here&#39;s a roundup of top developments in the biotech space over the last 24 hours:
<h3>Stocks In Focus</h3>
<h3>AbbVie&#39;s Rinvoq Gets Label Expansion To Treat Ulcerative Colitis</h3>
AbbVie, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/abbv#NYSE">ABBV</a>) announced&nbsp;the Food and Drug Administration has approved its Rinvoq for the treatment of adults with moderately to severely active ulcerative colitis, who have had an inadequate response or intolerance to one or more tumor necrosis factor blockers. This FDA approval is the first indication for <a href="https://www.benzinga.com/general/biotech/21/09/22969049/abbvie-submits-upadacitinib-applications-in-us-europe-for-ulcerative-colitis"> Rinvoq </a> in gastroenterology.
<h3>AstraZeneca&#39;s Antibody Cocktail Gets UK Regulatory Nod For Preventing COVID-19; UK Biopharma Announces $775M Settlement Agreement</h3>
AstraZeneca plc&#39;s (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/azn#NASDAQ">AZN</a>) antibody cocktail Evusheld was authorized for preventing COVID-19 by the U.K. drug regulator, the Medicines And Healthcare Products Regulatory Agency. Evusheld is a combination of two long-acting antibodies that works by binding to the spike protein on the outside of the SARS-CoV-2 virus, the virus that causes COVID-19. This in turn prevents the virus from attaching to and entering human cells.
Separately, AstraZeneca and its <a href="https://www.benzinga.com/general/biotech/20/12/18763050/astrazeneca-to-buy-rare-disease-specialist-drugmaker-alexion-for-39-billion">Alexion unit </a> said they hvae entered into a settlement agreement with Chugai Pharmaceuticals Co. Ltd. (OTC: <a class="ticker" href="https://www.benzinga.com/stock/chgcy#OTC">CHGCY</a>) to resolving all patent disputes between the two companies related to Ultomiris.
Under the terms of the agreement, Alexion will make a single payment of $775 million in the second quarter of 2022. The settlement does not impact AstraZeneca&#39;s financial guidance for 2022.
AstraZeneca shares were down 0.79% at $61.47 in premarket trading.
<h3>Stealth BioTherapeutics Announces Positive Preclinical Data For DMD Treatment Candidate</h3>
Stealth BioTherapeutics Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mito#NASDAQ">MITO</a>) presented at the 2022 Muscular Dystrophy Association and Clinical and Scientific Conference with new data demonstrating the potential synergistic relationship between elamipretide and an exon skipping phosphorodiamidate morpholino oligomer in the X-linked muscular dystrophy mouse model.
&quot;These data demonstrating the promise of combined elamipretide and PMO therapies offer early support for this premise, energizing our efforts to develop improved therapeutic options for DMD patients,&quot; said Reenie MacCarthy, CEO of Stealth.
The stock was adding 11.13% to $63.90 in premarket trading.
Related Link: <a href="https://www.benzinga.com/general/biotech/22/03/26115422/the-week-ahead-in-biotech-march-13-19-bristol-myers-squibbs-melanoma-drug-decision-multiple-confe">The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb&#39;s Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings </a>
<h3>Clover Reports Positive Data For COVID-19 Vaccine Candidate As Booster Dose Against Omicron Variant</h3>
Chinese biopharma Clover is developing a COVID-19 vaccine candidate&nbsp;named SCB-2019 that uses Dynavax Technologies Corporation&#39;s (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dvax#NASDAQ">DVAX</a>) CpG 1018 advanced adjuvant and aluminum hydroxide. Clover&nbsp;reported positive results from several studies evaluating the investigational vaccine. The company noted that 100% efficacy was maintained against severe COVID-19 and 95% efficacy against hospitalization at five months after the second dose.
A booster dose of SCB-2019 also produced significant neutralizing antibodies against the omicron variant in both homologous and heterologous settings.
<h3>BridgeBio Shares Gain On Insider Buying</h3>
BridgeBio Pharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bbio#NASDAQ">BBIO</a>) disclosed in a filing that Douglas Dachille, a director of the company&#39;s board, acquired 10,000 shares in the company.
The stock was adding 3.85% to $9.70 in premarket trading.
Click <a href="https://www.benzinga.com/fda-biotech#historical"> here </a> to access Benzinga&#39;s FDA calendar.
<h3>On The Radar</h3>
<h3>Clinical Readouts/Presentations</h3>
Eiger BioPharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eigr#NASDAQ">EIGR</a>) will host a conference call at 8:30 a.m. EDT&nbsp;to discuss the results from the Phase 3 TOGETHER study of Peginterferon Lambda for COVID-19.
Karyopharm Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kpti#NASDAQ">KPTI</a>) will present at the Society of Gynecologic Oncology Annual Meeting on Women&#39;s Cancer, Phase 3 data for oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer.
<h3>Earnings</h3>
<ul>
<li>Liquidia Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lqda#NASDAQ">LQDA</a>) (before the market open)</li>
<li>Synlogic, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sybx#NASDAQ">SYBX</a>) (before the market open)</li>
<li>Acutus Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/afib#NASDAQ">AFIB</a>) (before the market open)</li>
<li>MediWound Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mdwd#NASDAQ">MDWD</a>) (before the market open</li>
<li>X4 Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xfor#NASDAQ">XFOR</a>) (before the market open)</li>
<li>Aldeyra Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aldx#NASDAQ">ALDX</a>) (before the market open)</li>
<li>CymaBay Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cbay#NASDAQ">CBAY</a>) (after the close)</li>
<li>Spectrum Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sppi#NASDAQ">SPPI</a>) (after the close)</li>
<li>Avadel Pharmaceuticals plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avdl#NASDAQ">AVDL</a>) (after the close)</li>
<li>Onconova Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ontx#NASDAQ">ONTX</a>) (after the close)</li>
<li>Trevi Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trvi#NASDAQ">TRVI</a>) (after the close)</li>
</ul>
Related Link: <a href="https://www.benzinga.com/general/biotech/22/03/25864798/attention-biotech-investors-mark-your-calendar-for-march-pdufa-dates">Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates </a>

Earnings

Penny Stocks

Small Cap

ABBV

AFIB

ALDX

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

BBIO

CBAY

DVAX

EIGR

KPTI

LQDA

MDWD

MITO

ONTX

SPPI

SYBX

TRVI

XFOR

The Daily Biotech Pulse: AbbVie's Rinvoq Gets Label Expansion, AstraZeneca COVID Antibody Cocktail Authorized By UK Regulator, Stealth Touts Positive Data

Major indices worldwide were tepid on Tuesday, except for China. Traders were cautious following Wall Street&rsquo;s decline on Monday, as GOP lawmakers are considering outgoing President&nbsp;<a class="editor-rtfLink" href="https://edition.cnn.com/2021/01/11/politics/peter-meijer-trump-impeachment-cnntv/index.html" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">Donald Trump&rsquo;s impeachment</a>.
The Dow futures are up by 0.24%, and the S&amp;P 500 futures are trading higher by 0.26% on the last check Tuesday. WTI crude futures are up by 1.24% to $52.90, and gold futures are up 0.21% at $1,854.70. Ten-year Treasury yield is up by 2.1 bps at 1.155%.
<a class="editor-rtfLink" href="https://www.benzinga.com/money/is-bitcoin-a-good-investment/" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">Bitcoin</a>&nbsp;recovered from lows of $30,635 to trade 1.60% higher at $36,073, and Ethereum was up 0.92% at $1,121.10 on the last check. Bitcoin trading volume remained high&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/markets/cryptocurrency/21/01/19114410/bitcoin-trading-volume-active-addresses-hit-record-high-despite-slump-what-that-means" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">despite the slump</a>. Some have called the&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/markets/cryptocurrency/21/01/19114888/unfazed-by-a-plunging-bitcoin-proponents-dub-pull-back-necessary-healthy" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">pullback in cryptocurrency</a>&nbsp;&ldquo;healthy.&rdquo; The VIX futures are down by 2.35% to 23.90.
Asia:&nbsp;Japan&rsquo;s Nikkei 225 closed higher by 0.09%, coming from a holiday. The nation&rsquo;s bank lending rose 6.2% year-over-year, and the current adjusted current account expanded to &yen;2.34 trillion.&nbsp;Chugai Pharmaceutical Co Ltd&nbsp;(OTC: <a class="ticker" href="https://www.benzinga.com/stock/chgcy#OTC">CHGCY</a>) gained 5.9% in Tokyo on reports that its drug <a href="http://www.reuters.com/article/japan-stocks-close/nikkei-ends-at-30-yr-high-as-drug-makers-rally-on-covid-19-treatment-news-idUSL4N2JN1AY">effectively treated&nbsp;COVID-19 patients</a>.
China&rsquo;s Shanghai Composite rallied 2.18% after President Xi Jinping&nbsp;<a class="editor-rtfLink" href="https://www.bloomberg.com/news/articles/2021-01-12/upbeat-xi-says-time-on-china-s-side-as-turmoil-grips-u-s?sref=TBDibEcD" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">issued an upbeat assessment</a>&nbsp;about China&rsquo;s future, saying that &ldquo;time and the situation&rdquo; were on its side. Despite the rise in coronavirus infections in northern&nbsp;<a class="editor-rtfLink" href="https://www.reuters.com/article/china-stocks-close/china-stocks-rebound-blue-chip-index-ends-at-13-yr-high-idUSAZN00RZW8" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">China and Sino-U.S. tensions</a>, financials, consumer, and industrial stocks rallied.
Australia&rsquo;s S&amp;P/ASX 200 closed 0.27% lower, as mining stocks fell for the third straight session. Hong Kong&rsquo;s Hang Seng gained 1.32% on capital inflows from&nbsp;<a class="editor-rtfLink" href="https://www.reuters.com/article/china-stocks-hongkong-close/hong-kong-stocks-end-at-near-1-yr-high-on-capital-inflows-from-mainland-idUSAZN18VF00" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">mainland China</a>.&nbsp;
India&rsquo;s Nifty 50 index is trading higher by 0.58% at publication time, led by gains in autos in bank stocks. CPI and industrial production data are due later today.
South Korea&rsquo;s KOSPI closed lower by 0.71%. December&rsquo;s unemployment rate for December is due today.
Europe:&nbsp;Euro Stoxx 50 is trading marginally higher by 0.07% at press time, as investors look forward to the&nbsp;<a class="editor-rtfLink" href="https://www.reuters.com/article/europe-stocks/european-stocks-rebound-as-oil-travel-stocks-jump-idUSL4N2JN1VR" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">upcoming earnings season</a>.
London&rsquo;s FTSE 100 is down by 0.23% at publication time. U.K.&rsquo;s retail sales grew 4.8% YoY in December.
Germany&rsquo;s DAX is trading higher by 0.30%, led higher by banks and technology stocks.
France&rsquo;s CAC 40 is trading near flat, and Spain&rsquo;s IBEX 35 is up 0.31%.
<a class="editor-rtfLink" href="http://www.benzinga.com/money/how-to-trade-forex" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">Forex Trading</a>: U.S. Dollar Index futures are down 0.08% to 90.362. The dollar has weakened 0.14% against the Euro, 0.55% against the Sterling Pound, 0.06% against the Japanese Yen, and 0.28% against the Chinese Yuan.
For news coverage in Italian or Spanish, check out&nbsp;<a class="editor-rtfLink" href="https://it.benzinga.com/" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">Benzinga Italia</a>&nbsp;and&nbsp;<a class="editor-rtfLink" href="https://es.benzinga.com/" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">Benzinga Espa&ntilde;a</a>.

Comments

Chugai Pharmaceutical

空売り

Chugai Pharmaceutical (OTC:CHGCY) 株価情報, 空売り情報

ニュース

パートナーシップ

ベンジンガ・グローバル